Oligonucleotide, Therapy, and Applications
Oligonucleotides (ON) constitute a new group of molecular agents, the object of significant interest due to their potential value as drugs for diagnostic and therapeutic applications. Their special interest derives from the intrinsic characteristics of ONs: a) ONs are informative agents, a property...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (123 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545738104498 |
---|---|
ctrlnum |
(CKB)5400000000045243 (oapen)https://directory.doabooks.org/handle/20.500.12854/79571 (EXLCZ)995400000000045243 |
collection |
bib_alma |
record_format |
marc |
spelling |
Aliño, Salvador edt Oligonucleotide, Therapy, and Applications Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (123 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Oligonucleotides (ON) constitute a new group of molecular agents, the object of significant interest due to their potential value as drugs for diagnostic and therapeutic applications. Their special interest derives from the intrinsic characteristics of ONs: a) ONs are informative agents, a property that derives from the order in which the nucleotides of each particular ON are arranged; b) ONs can act as ligands (ASO, TFO, aptamers, G-quadruplex, etc.) of complementary nucleic acid sequences (DNA or RNA) due to their high capacity to hybridize (by means of Watson and Crick or Hoogsteen links) with other nucleotide sequences, resulting in specific gene modulatory effects. However, nonspecific sequences may also be of interest, as is the case with repetitive nucleotide sequences (CpG) with adjuvant effects of vaccines; c) ONs can also rapidly evolve to achieve specific advantages of utility (targeting, stability, efficacy, toxicity, etc.) or high-sensitivity diagnostic technology (markers, analyzes, biosensors, FISH, microarrays, etc.), by chemical modification of nucleotides in any of their atoms. These properties show that ONs are first-order molecules due to their potential usefulness in practice.In this collection of research articles and review papers, we aim to highlight their therapeutic, but also diagnostic and technological utility as drugs. English Medicine bicssc quantum dots (QDs) DNAzyme ROS Amplex Red light-induced activity DNA methylation histone code microRNA nanoparticles noncoding RNA pulmonary arterial hypertension aptamer aptasensor influenza SERS virus detection α-synuclein antisense oligonucleotide dopamine neurotransmission double mutant A30P*A53T* motor deficits Parkinson’s disease transgenic mouse model G-quadruplexes covalent dimer construct anti-proliferative activity primary cell culture of human glioma antisensense oligonucleotide Foxp3 regulatory T cells vaccine immunogenicity Sporothrix schenckii Marfan syndrome fibrillin-1 antisense oligonucleotides exon skipping splice-switching 3-0365-3057-6 3-0365-3056-8 Sendra, Luis edt Aliño, Salvador oth Sendra, Luis oth |
language |
English |
format |
eBook |
author2 |
Sendra, Luis Aliño, Salvador Sendra, Luis |
author_facet |
Sendra, Luis Aliño, Salvador Sendra, Luis |
author2_variant |
s a sa l s ls |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Oligonucleotide, Therapy, and Applications |
spellingShingle |
Oligonucleotide, Therapy, and Applications |
title_full |
Oligonucleotide, Therapy, and Applications |
title_fullStr |
Oligonucleotide, Therapy, and Applications |
title_full_unstemmed |
Oligonucleotide, Therapy, and Applications |
title_auth |
Oligonucleotide, Therapy, and Applications |
title_new |
Oligonucleotide, Therapy, and Applications |
title_sort |
oligonucleotide, therapy, and applications |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (123 p.) |
isbn |
3-0365-3057-6 3-0365-3056-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT alinosalvador oligonucleotidetherapyandapplications AT sendraluis oligonucleotidetherapyandapplications |
status_str |
n |
ids_txt_mv |
(CKB)5400000000045243 (oapen)https://directory.doabooks.org/handle/20.500.12854/79571 (EXLCZ)995400000000045243 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Oligonucleotide, Therapy, and Applications |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1787548726668034049 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03572nam-a2200757z--4500</leader><controlfield tag="001">993545738104498</controlfield><controlfield tag="005">20231214133328.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202203s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045243</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/79571</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045243</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Aliño, Salvador</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oligonucleotide, Therapy, and Applications</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (123 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oligonucleotides (ON) constitute a new group of molecular agents, the object of significant interest due to their potential value as drugs for diagnostic and therapeutic applications. Their special interest derives from the intrinsic characteristics of ONs: a) ONs are informative agents, a property that derives from the order in which the nucleotides of each particular ON are arranged; b) ONs can act as ligands (ASO, TFO, aptamers, G-quadruplex, etc.) of complementary nucleic acid sequences (DNA or RNA) due to their high capacity to hybridize (by means of Watson and Crick or Hoogsteen links) with other nucleotide sequences, resulting in specific gene modulatory effects. However, nonspecific sequences may also be of interest, as is the case with repetitive nucleotide sequences (CpG) with adjuvant effects of vaccines; c) ONs can also rapidly evolve to achieve specific advantages of utility (targeting, stability, efficacy, toxicity, etc.) or high-sensitivity diagnostic technology (markers, analyzes, biosensors, FISH, microarrays, etc.), by chemical modification of nucleotides in any of their atoms. These properties show that ONs are first-order molecules due to their potential usefulness in practice.In this collection of research articles and review papers, we aim to highlight their therapeutic, but also diagnostic and technological utility as drugs.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">quantum dots (QDs)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNAzyme</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ROS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Amplex Red</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">light-induced activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA methylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">histone code</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">noncoding RNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary arterial hypertension</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aptamer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aptasensor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">influenza</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SERS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virus detection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">α-synuclein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antisense oligonucleotide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dopamine neurotransmission</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">double mutant A30P*A53T*</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">motor deficits</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Parkinson’s disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transgenic mouse model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">G-quadruplexes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">covalent dimer construct</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-proliferative activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">primary cell culture of human glioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antisensense oligonucleotide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Foxp3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulatory T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccine immunogenicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Sporothrix schenckii</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Marfan syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fibrillin-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antisense oligonucleotides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exon skipping</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">splice-switching</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3057-6</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3056-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sendra, Luis</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aliño, Salvador</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sendra, Luis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:50:23 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338053990004498&Force_direct=true</subfield><subfield code="Z">5338053990004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338053990004498</subfield></datafield></record></collection> |